Skip to main content

Tamoxifen Citrate

Brand names: Tamoxifen Citrate, Soltamox

Estrogen Agonist/Antagonist Oral

At a glance

Medicare prescriptions, 2024
304,289
Medicare drug cost
$8.1M
Average cost per prescription
$26.68
Clinicians who prescribed it
8,509

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

What it is used for

SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS) To reduce the incidence of breast cancer in adult women at high risk

From the FDA-approved prescribing information (label dated November 2021). Full labels on DailyMed (opens in a new tab)

Boxed warning

WARNING: UTERINE MALIGNANCIES and THROMBOEMBOLIC EVENTS Serious and life-threatening events from the use of SOLTAMOX include uterine malignancies, stroke, and pulmonary embolism. Fatal cases of each type of event have occurred. Incidence rates per 1000 women-years for these events were estimated from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial in women at high risk for breast cancer: Endometrial adenocarcinoma: 2.20 for tamoxifen vs. 0.71 for placebo Uterine sarcoma: 0.17 for tamoxifen vs. 0.04 for placebo Stroke: 1.43 for tamoxifen vs. 1.00 for placebo. Pulmonary embolism: 0.75 for tamoxifen versus 0.25 for placebo. Discuss the potential benefits of tamoxifen versus the potential risks of these serious events with women at high risk for breast cancer and women with ductal carcinoma in situ (DCIS) considering tamoxifen to reduce the risk of developing…

The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.

Who prescribes it

All prescribers, by place, name or specialty →

Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.

Trend, 2019–2024

Medicare prescriptions fell 9% from 2019 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 2019419,579
  • 2020402,932
  • 2021385,371
  • 2022378,297
  • 2023372,705
  • 2024383,463

Biggest change by state since 2019

  • Washington +6%
  • Colorado +4%
  • Indiana +4%
  • Oregon +3%
  • Maryland +3%
  • Ohio (smallest change) −22%
  • Puerto Rico (smallest change) −22%

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

A-S Medication Solutions

StrengthLooks likeImprint
10 mgwhite round tablet, 8 mm2232 WPI

Bryant Ranch Prepack

StrengthLooks likeImprint
10 mgwhite round tablet, 8 mm2232 WPI

Mylan Pharmaceuticals Inc.

StrengthLooks likeImprint
10 mgwhite round tablet, 7 mmM 144
20 mgwhite round tablet, 10 mmM 274

Nucare Pharmaceuticals, Inc.

StrengthLooks likeImprint
10 mgwhite round tablet, 7 mmT10

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

No industry payments to clinicians named this drug in 2025.

Recalls and shortages

Not on the FDA drug shortage list.

No FDA-reported recalls since 2020.

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.